StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Wolfe Research on Eli Lilly (LLY): ph3 retratrutide results point to potential 'best-in-class' weight loss
March 19, 2026 8:31 AM
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $1,325.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
